Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Zevra Therapeutics (ZVRA) Asset Writedowns and Impairment (2024 - 2025)

Zevra Therapeutics' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $47.0 million for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment rose 9305.8% year-over-year to $47.0 million; the TTM value through Dec 2025 reached $106.2 million, up 2771.32%, while the annual FY2025 figure was $58.7 million, 930.0% up from the prior year.
Asset Writedowns and Impairment reached $47.0 million in Q4 2025 per ZVRA's latest filing, down from $58.7 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $58.7 million in Q2 2025 to a low of $500000.0 in Q4 2024.